AR116115A1 - Dimetil amino azetidina amidas como inhibidores de jak - Google Patents
Dimetil amino azetidina amidas como inhibidores de jakInfo
- Publication number
- AR116115A1 AR116115A1 ARP190102520A ARP190102520A AR116115A1 AR 116115 A1 AR116115 A1 AR 116115A1 AR P190102520 A ARP190102520 A AR P190102520A AR P190102520 A ARP190102520 A AR P190102520A AR 116115 A1 AR116115 A1 AR 116115A1
- Authority
- AR
- Argentina
- Prior art keywords
- dimethyl amino
- jak inhibitors
- compounds
- amino azetidine
- amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente provee compuestos de fórmula (1) en donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de los mismos, que son útiles como inhibidores de la quinasa JAK. La presente también provee composiciones farmacéuticas que comprenden dichos compuestos y métodos para usar dichos compuestos para tratar enfermedades respiratorias. Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: n es 0, 1 ó 2; R¹ es C₁₋₃ alquilo; cada R² es en forma independiente C₁₋₃ alquilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726562P | 2018-09-04 | 2018-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116115A1 true AR116115A1 (es) | 2021-03-31 |
Family
ID=67982186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102520A AR116115A1 (es) | 2018-09-04 | 2019-09-03 | Dimetil amino azetidina amidas como inhibidores de jak |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10947229B2 (es) |
| EP (1) | EP3837258B1 (es) |
| JP (2) | JP7324836B2 (es) |
| KR (1) | KR102826491B1 (es) |
| CN (1) | CN112739697B (es) |
| AR (1) | AR116115A1 (es) |
| AU (1) | AU2019336167B2 (es) |
| BR (1) | BR112021004052A2 (es) |
| CL (1) | CL2021000514A1 (es) |
| CO (1) | CO2021002977A2 (es) |
| DK (1) | DK3837258T3 (es) |
| EA (1) | EA202190681A1 (es) |
| ES (1) | ES2982858T3 (es) |
| FI (1) | FI3837258T3 (es) |
| HR (1) | HRP20241002T1 (es) |
| HU (1) | HUE068058T2 (es) |
| IL (1) | IL281146B2 (es) |
| LT (1) | LT3837258T (es) |
| MA (1) | MA53229A (es) |
| MX (1) | MX2021002521A (es) |
| PH (1) | PH12021550368A1 (es) |
| PL (1) | PL3837258T3 (es) |
| PT (1) | PT3837258T (es) |
| SG (1) | SG11202101734RA (es) |
| SI (1) | SI3837258T1 (es) |
| TW (1) | TWI791886B (es) |
| WO (1) | WO2020051105A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| JP7383696B2 (ja) | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| WO2021226637A1 (en) * | 2020-05-08 | 2021-11-11 | Theravance Biopharma R&D Ip, Llc | Method of treating a patient infected with a coronavirus with nezulcitinib |
| WO2022271604A1 (en) * | 2021-06-21 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l |
| CA3223194A1 (en) * | 2021-06-25 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Imidazolo indazole compounds as jak inhibitors |
| EP4450492A4 (en) * | 2021-12-17 | 2025-10-15 | Daewoong Pharmaceutical Co Ltd | NEW ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R,3S)-2-(3-(4,5-DICHLORO-1H-BENZO[D]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL |
| US20250288561A1 (en) * | 2022-05-05 | 2025-09-18 | Theravance Biopharma R&D Ip, Llc | Nezulcitinib for delivery by nebulized oral inhalation |
| WO2023230236A1 (en) | 2022-05-26 | 2023-11-30 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| HUE035612T2 (en) | 2009-12-21 | 2018-05-28 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CR20160525A (es) | 2014-05-14 | 2016-12-20 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| ES2864035T3 (es) | 2015-11-03 | 2021-10-13 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus |
| US20180258546A1 (en) * | 2017-03-09 | 2018-09-13 | Lam Research Corporation | Electroplating apparatus and methods utilizing independent control of impinging electrolyte |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| SG11201909376TA (en) | 2017-05-01 | 2019-11-28 | Theravance Biopharma R&D Ip Llc | Crystalline forms of a jak inhibitor compound |
| CA3059785A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AU2019306651B2 (en) | 2018-07-20 | 2025-03-20 | Porifera, Inc. | Osmosis modules having recirculation loops |
| WO2020051135A1 (en) | 2018-09-04 | 2020-03-12 | Theravance Biopharma R&D Ip, Llc | Process for preparing jak inhibitors and intermediates thereof |
| JP7383696B2 (ja) * | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| BR112021004052A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas de dimetil-amino azetidina como inibidores de jak |
| CA3113667A1 (en) | 2018-10-29 | 2020-05-07 | Theravance Biopharma R&D Ip, Llc | 2-azabicyclo hexane compound as jak inhibitor |
| EP3932919B1 (en) | 2019-02-25 | 2024-06-26 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Jak inhibitor compound and use thereof |
| PH12021552130A1 (en) | 2019-03-05 | 2022-08-31 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
| TW202144343A (zh) * | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| WO2021226637A1 (en) | 2020-05-08 | 2021-11-11 | Theravance Biopharma R&D Ip, Llc | Method of treating a patient infected with a coronavirus with nezulcitinib |
| WO2022178215A1 (en) | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
| CN117083273A (zh) | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
| WO2022271604A1 (en) * | 2021-06-21 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l |
-
2019
- 2019-09-03 BR BR112021004052-8A patent/BR112021004052A2/pt unknown
- 2019-09-03 LT LTEPPCT/US2019/049276T patent/LT3837258T/lt unknown
- 2019-09-03 PL PL19769674.3T patent/PL3837258T3/pl unknown
- 2019-09-03 SI SI201930791T patent/SI3837258T1/sl unknown
- 2019-09-03 HR HRP20241002TT patent/HRP20241002T1/hr unknown
- 2019-09-03 MA MA053229A patent/MA53229A/fr unknown
- 2019-09-03 PH PH1/2021/550368A patent/PH12021550368A1/en unknown
- 2019-09-03 WO PCT/US2019/049276 patent/WO2020051105A1/en not_active Ceased
- 2019-09-03 IL IL281146A patent/IL281146B2/en unknown
- 2019-09-03 TW TW108131679A patent/TWI791886B/zh active
- 2019-09-03 AR ARP190102520A patent/AR116115A1/es not_active Application Discontinuation
- 2019-09-03 JP JP2021512257A patent/JP7324836B2/ja active Active
- 2019-09-03 EA EA202190681A patent/EA202190681A1/ru unknown
- 2019-09-03 KR KR1020217009936A patent/KR102826491B1/ko active Active
- 2019-09-03 AU AU2019336167A patent/AU2019336167B2/en active Active
- 2019-09-03 ES ES19769674T patent/ES2982858T3/es active Active
- 2019-09-03 US US16/559,077 patent/US10947229B2/en active Active
- 2019-09-03 FI FIEP19769674.3T patent/FI3837258T3/fi active
- 2019-09-03 PT PT197696743T patent/PT3837258T/pt unknown
- 2019-09-03 EP EP19769674.3A patent/EP3837258B1/en active Active
- 2019-09-03 CN CN201980057577.7A patent/CN112739697B/zh active Active
- 2019-09-03 HU HUE19769674A patent/HUE068058T2/hu unknown
- 2019-09-03 DK DK19769674.3T patent/DK3837258T3/da active
- 2019-09-03 SG SG11202101734RA patent/SG11202101734RA/en unknown
- 2019-09-03 MX MX2021002521A patent/MX2021002521A/es unknown
-
2021
- 2021-02-04 US US17/248,717 patent/US11634419B2/en active Active
- 2021-03-02 CL CL2021000514A patent/CL2021000514A1/es unknown
- 2021-03-04 CO CONC2021/0002977A patent/CO2021002977A2/es unknown
-
2022
- 2022-09-06 JP JP2022141182A patent/JP2022172299A/ja active Pending
-
2023
- 2023-03-09 US US18/181,138 patent/US20230322774A1/en not_active Abandoned
-
2024
- 2024-05-31 US US18/680,940 patent/US12398135B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| MX2019010539A (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterociclica de 4 miembros como inhibidores de jak. | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| CY1121062T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| MX2018010177A (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida. | |
| AR098319A1 (es) | Profármacos de antagonista de nmda | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| CY1122375T1 (el) | Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos | |
| AR113794A1 (es) | Inhibidores de trpc6 | |
| EA201892640A1 (ru) | Лечение болезни паркинсона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |